CMV Prevention After Stem Cell Transplant Using Blood Tests
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had an allogeneic stem cell transplant (receiving stem cells from a donor to treat blood cancer or disease)
- You were exposed to CMV before transplant (a virus many people have had, detected by a blood test)
- You are at least 18 years old
- Your doctors expect you to survive longer than 6 months
- You do not currently have an active CMV infection or disease
- You can take letermovir safely (no severe liver or kidney problems, not pregnant or breastfeeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.